Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Gemcitabine-Cisplatin in First-line Advanced Urothelial Bladder Cancer
NCT03324282Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Feb 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in urothelial bladder carcinoma (UBC), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Feb 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
urothelial bladder carcinoma (UBC)
Beyond the preview
Go deeper on NCT03324282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324282.